PubHawk
N Engl J Med December 2015 PMID 26630143

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis, Aldo P Maggioni, John J V McMurray, Jeffrey L Probstfield, Matthew C Riddle, Scott D Solomon

Full text PDF Download social card

Mentions

40
Peak: 3 in Jan 2021
across 5 sources since Apr 2020

Extended reach

158,471
potential audience

Total likes

2,250

Video views

93,540

Mentions per month

Apr 2020 – Dec 2022

Where it's discussed

  • News15 articles
  • X / Twitter11 posts
  • Facebook9 posts
  • Blogs3 articles
  • YouTube2 videos

AI synopsis

What people are saying

The overall discussions acknowledge that the study confirms lixisenatide's cardiovascular safety but lacks superiority, as seen in phrases like 'Lixisenatide showed CV safety but not superiority,' which reveal moderate interest and engagement. The tone combines cautious acknowledgment with curiosity about its implications, illustrating a balanced view of its potential impact.

AgreementModerate agreement

Most discussions acknowledge the study's findings that lixisenatide demonstrates cardiovascular safety but does not show superiority, indicating a general consensus on its safety profile.

InterestModerate interest

The posts show a moderate level of curiosity, often referencing related drug trials or comparing different diabetes medications, suggesting some engagement but limited deep exploration.

EngagementModerate engagement

Numerous discussions cite specific studies like ELIXA or PIONEER 6, and question implications, reflecting a thoughtful but not highly detailed engagement.

ImpactModerate impact

The collective tone indicates recognition that the publication clarifies the safety of lixisenatide, though its influence on clinical practice appears to be viewed as moderate rather than transformative.

Abstract in brief

  • This study investigated the effects of lixisenatide, a medication for type 2 diabetes, on cardiovascular outcomes in patients who recently experienced a heart attack or unstable angina, finding it to be noninferior to placebo in preventing major cardiovascular events.
  • Over a median follow-up of 25 months with 6068 patients, there was no significant difference between lixisenatide and placebo groups in rates of hospitalization for heart failure or death, and lixisenatide did not show superiority in reducing these events.
  • Lixisenatide was generally safe, as it did not increase serious adverse events like hypoglycemia, pancreatitis, or allergic reactions compared to placebo in this high-risk patient population.
Read the full abstract

Top posts

Most liked on X and Bluesky
おだQ
@OdaQ_DM · X

GLP-1受容体作動薬の心血管エビデンス一覧2 ・リキセナチド（商品名リキスミア) ELIXA https://t.co/xuafQgvrFE ・セマグルチド(商品名オゼンピック) SUSTAIN 6 https://t.co/GbRauHohsf PIONEER 6(経口) https://t.co/DcznGmE55E ・アルビグルチド(日本非発売) HARMONY OUTCOMES

Jun 16, 2020 · 15 likes · 1 share · 15,251 followers View post →
Juan Senior
@jsenior64 · X

Agonistas GLP-1 y desenlaces cardiovasculares. ¿Comparables a los ISGLT-2? https://t.co/TrgCbkW0yl

Jan 11, 2021 · 5 likes · 4 shares · 11,087 followers View post →
cardio-met
@cardiomet_CE · X

Lixisenatide showed CV safety but not superiority https://t.co/bNlGY8cN2A

Jul 9, 2021 · 4 likes · 2 shares · 4,217 followers View post →
cardio-met
@cardiomet_CE · X

24c)

May 11, 2022 · 2 likes · 4,217 followers View post →
Juan Senior
@jsenior64 · X

https://t.co/TrgCbkW0yl

Aug 16, 2022 · 11,087 followers View post →
Juan Senior
@jsenior64 · X

RT @jsenior64: Agonistas GLP-1 y desenlaces cardiovasculares. ¿Comparables a los ISGLT-2? https://t.co/TrgCbkW0yl

Mar 1, 2021 · 4 shares · 11,087 followers View post →

All mentions

Understanding GLP-1 Medications for Type 2 Diabetes

Ever wonder about medications like Trulicity, Ozempic, or Victoza? This video discusses the role of GLP-1 in managing blood glucose levels, how these medications function, their benefits, and potential side effects…

Sugar High · Apr 30, 2020 93,306 views
Maddalena Ardissino
@DrMArdissino · X

@CMichaelGibson Be careful!! The references there are all inaccurate! Paste them into search bar to find out. e.g., the NEJM one is for the Lixesanatide study in T2DM+ACS (not Praluent!) https://t.co/9I1I5ImCZc

Dec 7, 2022 · 940 followers View post →
Juan Senior
@jsenior64 · X

https://t.co/TrgCbkW0yl

Aug 16, 2022 · 11,087 followers View post →
cardio-met
@cardiomet_CE · X

24c)

May 11, 2022 · 2 likes · 4,217 followers View post →
Kevin Fernando
@drkevinfernando · X

RT @cardiomet_CE: Lixisenatide showed CV safety but not superiority https://t.co/bNlGY8cN2A

Jul 9, 2021 · 2 shares · 5,141 followers View post →
Charles Pollack MD
@md_pollack · X

RT @cardiomet_CE: Lixisenatide showed CV safety but not superiority https://t.co/bNlGY8cN2A

Jul 9, 2021 · 2 shares · 279 followers View post →
cardio-met
@cardiomet_CE · X

Lixisenatide showed CV safety but not superiority https://t.co/bNlGY8cN2A

Jul 9, 2021 · 4 likes · 2 shares · 4,217 followers View post →
Juan Senior
@jsenior64 · X

RT @jsenior64: Agonistas GLP-1 y desenlaces cardiovasculares. ¿Comparables a los ISGLT-2? https://t.co/TrgCbkW0yl

Mar 1, 2021 · 4 shares · 11,087 followers View post →
Dr Carlos Palacio - Diabetes
@PalacioDr · X

RT @jsenior64: Agonistas GLP-1 y desenlaces cardiovasculares. ¿Comparables a los ISGLT-2? https://t.co/TrgCbkW0yl

Jan 11, 2021 · 4 shares · 93 followers View post →
RAFAEL BRA
@rafael52987 · X

RT @jsenior64: Agonistas GLP-1 y desenlaces cardiovasculares. ¿Comparables a los ISGLT-2? https://t.co/TrgCbkW0yl

Jan 11, 2021 · 4 shares · 1,486 followers View post →
Juan Senior
@jsenior64 · X

Agonistas GLP-1 y desenlaces cardiovasculares. ¿Comparables a los ISGLT-2? https://t.co/TrgCbkW0yl

Jan 11, 2021 · 5 likes · 4 shares · 11,087 followers View post →
おだQ
@OdaQ_DM · X

GLP-1受容体作動薬の心血管エビデンス一覧2 ・リキセナチド（商品名リキスミア) ELIXA https://t.co/xuafQgvrFE ・セマグルチド(商品名オゼンピック) SUSTAIN 6 https://t.co/GbRauHohsf PIONEER 6(経口) https://t.co/DcznGmE55E ・アルビグルチド(日本非発売) HARMONY OUTCOMES

Jun 16, 2020 · 15 likes · 1 share · 15,251 followers View post →